Compare Amphastar Pharmaceuticals Inc (AMPH) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Mesoblast Limited — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.04 (market cap $868.62M), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Mesoblast Limited is far larger — about 2.5× Amphastar Pharmaceuticals Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | MESO | |
|---|---|---|
Market Cap | $868.62M | $2.21B |
Sector | Health | Technology |
52-Week High | $30.81 | $20.96 |
52-Week Low | $16.87 | $12.88 |
Enterprise Value | $1.27B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.98, down 1.62% today, with a bullish technical signal supported by moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.
The outlook is balanced with analyst consensus leaning Hold (66.67%) amid regulatory scrutiny and competitive pressures. Near-term catalysts include pipeline developments, but risks from FDA warnings and generic drug tariff uncertainties warrant caution. Cash flow trends improved with 2026 net cash flow projected at $36 million.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
